Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Prognostic Value of FDG PET/CT and Diffusion-weighed Imaging on Detection of Primary Tumor and Axillary Metastasis for Breast Cancer: SUVMax Against to ADC

NCT01942759 is registered in ClinicalTrials.gov with Bagcilar Training and Research Hospital as lead sponsor.

NCT NCT01942759
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01942759 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Prognostic Value of FDG PET/CT and Diffusion-weighed Imaging on Detection of Primary Tumor and Axillary Metastasis for Breast Cancer: SUVMax Against to ADC
Lead sponsor
Bagcilar Training and Research Hospital
Phase
Observational
Overall status
Completed
Start date
September 30, 2013
Completion date
June 30, 2014
Enrollment
43 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms